Novavax Reports $70 Million Q3 Revenue and Raises 2025 Revenue Framework
Novavax Inc. reported its financial results and operational highlights for the third quarter ended September 30, 2025. The company recorded total revenue of $70 million for the quarter. Revenues from its Sanofi partnership reached $48 million in the third quarter, a 33% increase compared to $36 million in the same period last year. Licensing, royalties, and other revenue totaled $57 million, up 33% from $43 million in the prior year quarter. Product sales declined to $13 million from $41 million in the third quarter of 2024, representing a 68% decrease. Nuvaxovid sales were reported at $0, down from $38 million a year earlier. Supply sales increased to $14 million from $3 million in the previous year. Novavax highlighted continued successful execution of its Sanofi partnership, earning $225 million in milestones year-to-date, including $50 million in the fourth quarter of 2025 from marketing authorization transfers for EU and US markets. The company also completed Maryland site consolidation transactions, resulting in $60 million in cash proceeds and an expected $230 million in future cost savings over 11 years. Novavax raised its full year 2025 revenue framework and affirmed its financial guidance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001000694-25-000048), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.